These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 21951758

  • 1. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M, Chapman R, Hughes O, Choi YH.
    BMJ; 2011 Sep 27; 343():d5775. PubMed ID: 21951758
    [Abstract] [Full Text] [Related]

  • 2. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

  • 4. Comparing bivalent and quadrivalent HPV vaccines.
    Verheijen RH.
    BMJ; 2011 Sep 27; 343():d5720. PubMed ID: 21951757
    [No Abstract] [Full Text] [Related]

  • 5. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 6. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.
    BMC Infect Dis; 2013 Feb 07; 13():75. PubMed ID: 23390964
    [Abstract] [Full Text] [Related]

  • 7. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M, Brisson M, Laprise JF, Choi YH.
    BMJ; 2015 Jan 06; 350():g7584. PubMed ID: 25567037
    [Abstract] [Full Text] [Related]

  • 8. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.
    BMC Public Health; 2017 Feb 02; 17(1):152. PubMed ID: 28148228
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of human papillomavirus vaccination in the United Kingdom.
    Jit M, Choi YH, Edmunds WJ.
    BMJ; 2008 Jul 17; 337():a769. PubMed ID: 18640957
    [Abstract] [Full Text] [Related]

  • 10. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 11. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, Arnheim-Dahlström L.
    JAMA; 2014 Feb 12; 311(6):597-603. PubMed ID: 24519299
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA, Gow J, Alam K, Keramat SA, Hossain MG, Sultana M, Sarker AR, Islam SMS.
    Vaccine; 2020 Jan 10; 38(2):165-172. PubMed ID: 31668820
    [Abstract] [Full Text] [Related]

  • 13. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y, Ni W, Wu J.
    BMJ Open; 2019 Nov 24; 9(11):e031186. PubMed ID: 31767588
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 Nov 24; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 16. Health and economic implications of HPV vaccination in the United States.
    Kim JJ, Goldie SJ.
    N Engl J Med; 2008 Aug 21; 359(8):821-32. PubMed ID: 18716299
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 Aug 21; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 18. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.
    Bresse X, Adam M, Largeron N, Roze S, Marty R.
    Hum Vaccin Immunother; 2013 Apr 21; 9(4):823-33. PubMed ID: 23563511
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.
    Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW.
    PLoS One; 2013 Apr 21; 8(11):e80639. PubMed ID: 24260441
    [Abstract] [Full Text] [Related]

  • 20. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.